The article highlights Vertex Pharmaceuticals' exceptional performance over the last 10 years, with an average annual return of 20.63%, which is likely to attract investor attention and potentially increase demand for VRTX shares in the short term. The significant outperformance compared to the market and the substantial growth of an initial investment could be seen as indicators of the company's strong fundamentals and operational success, potentially leading to positive sentiment among investors.